Physician profile
Mark Miranda
NPI 1558996215
$4,772.29
in general payments reported to CMS, 2019-2025
32 companies · $2,236 in 2025
The $2,236 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $113 · 2023: $738 · 2024: $1,686 · 2025: $2,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,461 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,460.80 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $481.21 | 2022-2025 | |
| Amgen INC. | $468.75 | 2024-2025 | Blincyto, Blincyto, Kyprolis |
| Pbg Puerto Rico LLC | $362.60 | 2024-2025 | |
| Incyte Corporation | $313.75 | 2023-2025 | Monjuvi, Jakafi, Pemazyre |
| Tempus Ai, INC | $287.52 | 2024-2025 | Xt Cdx |
| Adaptive Biotechnologies Corporation | $265.91 | 2024-2025 | Clonoseq |
| Rigel Pharmaceuticals, INC. | $250.05 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Taiho Oncology, INC. | $249.46 | 2023-2024 | |
| Abbvie INC. | $221.38 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $201.12 | 2024-2025 | Darzalex, Rybrevant, Talvey |
| Takeda Pharmaceuticals U.S.A., INC. | $160.04 | 2023-2025 | Iclusig, Advate |
| Genmab U.S., INC. | $147.47 | 2024-2025 | Epkinly |
| Astrazeneca Pharmaceuticals Lp | $146.81 | 2024-2025 | Calquence, Enhertu, Imfinzi |
| Regeneron Healthcare Solutions, INC. | $146.61 | 2024-2025 | Libtayo |
| Alexion Pharmaceuticals, INC. | $124.46 | 2023 | Ultomiris |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $122.48 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $122.09 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $121.55 | 2024-2025 | Keytruda, Welireg |
| Seagen INC. | $99.99 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $72.90 | 2024 | Opdivo, Reblozyl, Opdualag |
| Telix Pharmaceuticals | $70.85 | 2025 | Illuccix |
| Karyopharm Therapeutics INC. | $65.45 | 2023 | Xpovio |
| Glaxosmithkline, LLC. | $42.88 | 2025 | Zejula, Jemperli |
| Genentech USA, INC. | $39.79 | 2024-2025 | Itovebi, Tecentriq |
| Emd Serono, INC. | $37.19 | 2024 | |
| Adc Therapeutics America, INC. | $23.95 | 2025 | |
| Bayer Puerto Rico INC. | $22.74 | 2024 | Nubeqa, Stivarga |
| Aveo Pharmaceuticals, INC. | $22.55 | 2025 | |
| Servier Pharmaceuticals LLC | $22.26 | 2025 | |
| Caris Mpi, INC. | $21.42 | 2025 | Mi Cancer Seek |
| Pfizer INC. | $19.33 | 2024 | |
| Eisai INC. | $17.73 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Miranda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.